SEC Comment Letter 0000000000-26-003141 to SUTRO BIOPHARMA, INC. (STRO)
SUTRO BIOPHARMA, INC.
Date: March 27, 2026 · CIK: 0001382101 · Accession: 0000000000-26-003141
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-294541
Letter
Re: Sutro Biopharma, Inc. Registration Statement on Form S-3 Filed March 23, 2026 File No. 333-294541 Dear Jane Chung:
March 27, 2026
Jane Chung Chief Executive Officer Sutro Biopharma, Inc. 111 Oyster Point Blvd. South San Francisco, California
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Ryan Mitteness, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 27, 2026 Jane Chung Chief Executive Officer Sutro Biopharma, Inc. 111 Oyster Point Blvd. South San Francisco, California Re: Sutro Biopharma, Inc. Registration Statement on Form S-3 Filed March 23, 2026 File No. 333-294541 Dear Jane Chung: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Ryan Mitteness, Esq. </TEXT> </DOCUMENT>